Abstract
Peritoneal dissemination is a frequent occurrence in pancreatic cancer, which is associated with a poor prognosis. MET is associated with the progression of pancreatic cancer; therefore, we evaluated the effect of a MET inhibitor, crizotinib, on peritoneal dissemination of pancreatic cancer. Crizotinib inhibited the growth of 8 pancreatic cancer cell lines with the IC50 ranging from 1.4 to 4.3 µM. Invasion of the pancreatic cancer cell line Suit-2, was suppressed in vitro at a concentration of 1.0 µM, which is sufficient for the inhibition of MET phosphorylation. This effect on cell invasion was also recapitulated by the reduction of MET expression in Suit-2 with siRNA. Crizotinib also inhibited RhoA activation in addition to MET phosphorylation. We further evaluated the effect of crizotinib on peritoneal dissemination of pancreatic cancer in vivo. Crizotinib reduced tumor burden and ascites accumulation due to development of peritoneal dissemination after inoculation of Suit-2. Taken together, crizotinib may be a potent drug for treating peritoneal dissemination of pancreatic cancer by inhibiting cancer cell proliferation and invasion, at least in part through the suppression of HGF/MET signaling and RhoA activation.
References
Feb 1, 1995·Molecular and Cellular Biology·A J RidleyA Hall
Dec 20, 2003·Nature Reviews. Molecular Cell Biology·Carmen BirchmeierGeorge F Vande Woude
Mar 31, 2004·Lancet·Donghui LiJames L Abbruzzese
Aug 6, 2004·Cell·Yibin Kang, Joan Massagué
Oct 8, 2005·Cell Motility and the Cytoskeleton·C M WellsG E Jones
Jul 27, 2006·Pancreas·Jörg KleeffMarkus W Büchler
May 8, 2007·Cancer Research·Helen Y ZouJames G Christensen
Jun 28, 2007·British Journal of Cancer·H UenoN Kaniwa
Dec 20, 2007·Molecular Cancer Therapeutics·James G ChristensenGerrit Los
Apr 3, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Shinji YamazakiTatiana Koudriakova
May 23, 2009·Biochemistry·Sergei L TimofeevskiBrion W Murray
Jun 3, 2009·The Journal of Clinical Investigation·Raghu Kalluri, Robert A Weinberg
Apr 30, 2010·The New England Journal of Medicine·Manuel Hidalgo
May 13, 2011·The New England Journal of Medicine·Thierry ConroyUNKNOWN PRODIGE Intergroup
Jan 25, 2012·Nature Reviews. Cancer·Ermanno GherardiGeorge Vande Woude
May 16, 2012·Cancer Discovery·Barbara SenninoDonald M McDonald
Feb 22, 2013·Molecular Cancer Therapeutics·Xingnan ZhengJian Yu
Oct 3, 2013·Cancer Research·Amir AvanElisa Giovannetti
Oct 18, 2013·The New England Journal of Medicine·Daniel D Von HoffMarkus F Renschler
Oct 22, 2013·Molecular Cancer Therapeutics·Oliver SurrigaGary K Schwartz
Oct 31, 2013·Molecular Cancer Therapeutics·Yan ZhouH Phillip Koeffler
Jul 31, 2014·The Journal of Pathology·Wei ZhouKlaus P Hoeflich
Sep 11, 2014·The New England Journal of Medicine·David P RyanNabeel Bardeesy
May 11, 2016·The Lancet Oncology·Mustafa SukerBas Groot Koerkamp
Citations
Feb 13, 2018·Oncology Letters·Tamami HiguchiTakayuki Asao
Aug 12, 2020·Cancer Metastasis Reviews·Leela Rani AvulaChristine Alewine
Aug 16, 2019·Genes·Wenzong LuFuyuan Liao
Dec 24, 2019·Frontiers in Oncology·Chen-Yu HuHang-Ping Yao
May 10, 2020·Journal of Clinical Pathology·Malene NielsenSönke Detlefsen
Mar 12, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Herbert J ZehMichael T Lotze
Nov 17, 2020·Frontiers in Cell and Developmental Biology·Zhiwei ShaoAnwen Shao
Dec 5, 2020·International Journal of Molecular Sciences·Srinivasa P PothulaMinoti V Apte
Apr 20, 2021·Frontiers in Medicine·Cangang ZhangHaibo Liu
Aug 3, 2021·Frontiers in Oncology·Penelope EdwardsIan Chau